Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naïve disease. Little information is available regarding the activity of single-ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Barata, Pedro, Hatton, Whitley, Desai, Arpita, Koshkin, Vadim, Jaeger, Ellen, Manogue, Charlotte, Cotogno, Patrick, Light, Malcolm, Lewis, Brian, Layton, Jodi, Sartor, Oliver, Basu, Arnab, Kilari, Deepak, Emamekhoo, Hamid, Bilen, Mehmet A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642690/
https://www.ncbi.nlm.nih.gov/pubmed/33194712
http://dx.doi.org/10.3389/fonc.2020.581189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642690/
https://www.ncbi.nlm.nih.gov/pubmed/33194712
http://dx.doi.org/10.3389/fonc.2020.581189

Ejemplares similares